The group aims to collect and sequence more than 2,500 blood samples by 2020 to improve primary diagnosis and treatment options for patients suffering from Parkinson's disease.
According to the researchers, led by a team at the University of Cambridge, detecting somatic brain mutations in patients during their life may increase diagnostic precision and lead to new therapies.
Centogene will collect dried blood spot samples and perform genetic analysis to find and recruit Parkinson's disease patients for Denali's LRRK2 inhibitor trials.
Scientific American reports that drugs being pursued to treat small fraction of Parkinson's disease patients with a certain gene mutation could also help a larger portion of patients.
Researchers from the French Parkinson's and Movement Disorders Consortium evaluated the diagnostic yield and cost of a 127-gene panel on nearly 400 patients.
The group will combine VIB's sequencing technology with Verge's machine learning platform to study banked tissue samples at UCSD in a drug discovery effort.
The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
